A dual regimen of entecavir (Baraclude) plus tenofovir
(Viread) for 48 weeks led to virological response and was generally
well-tolerated among people with chronic hepatitis B who had experienced treatment failure with previous
nucleoside/nucleotide analogue treatment, according to a poster presented earlier this month at The Liver Meeting 2013, the 64th annual
meeting of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC.
Chronic hepatitis B virus (HBV) infection
is treated with oral nucleoside/nucleotide analogues including lamivudine (Epivir), adefovir (Hepsera),
entecavir (Baraclude), telbivudine (Sebivo
or Tyzeka) and tenofovir (Viread). While these drugs can reduce
HBV viral load to an undetectable level while on therapy, they typically do not
lead to post-treatment sustained virological response or hepatitis B antigen
loss.
Read more... Labels: entecavir + tenofovir, prior treatment failure